eMedicine Specialties > Cardiology > Valvular Heart Disease

Aortic Stenosis: Differential Diagnoses & Workup

Author: John A McPherson, MD, FACC, FSCAI, Assistant Professor of Medicine, Division of Cardiovascular Medicine, Medical Director of Cardiovascular Intensive Care Unit, Vanderbilt Heart and Vascular Institute
Contributor Information and Disclosures

Updated: Aug 25, 2009

Differential Diagnoses

Mitral Regurgitation
Mitral Valve Prolapse

Other Problems to Be Considered

Supravalvular aortic stenosis
Congenital subvalvular aortic stenosis
Hypertrophic obstructive cardiomyopathy

Workup

Laboratory Studies

There is emerging data that B-type natriuretic peptide (BNP) may provide incremental prognostic information in predicting symptom onset in asymptomatic patients with severe aortic stenosis.

Imaging Studies

  • Echocardiography
    • Two-dimensional Doppler echocardiography is the imaging modality of choice to diagnose and estimate the severity of aortic stenosis and localize the level of obstruction. American College of Cardiology/American Heart Association (ACC/AHA) recommendations for echocardiography in aortic stenosis are summarized in Table 2. LV size, mass, and function should also be evaluated in each patient.
    • The etiology of aortic stenosis (bicuspid, rheumatic, or senile degenerative) may be assessed from the 2-dimensional echocardiographic parasternal short-axis view. Although the presence of aortic stenosis is readily diagnosed with 2-dimensional echocardiography, the severity of aortic stenosis cannot be judged based on the 2-dimensional echocardiographic images alone.

      Calcific aortic stenosis (parasternal long-axis a...

      Calcific aortic stenosis (parasternal long-axis and short-axis views).

      Calcific aortic stenosis (parasternal long-axis a...

      Calcific aortic stenosis (parasternal long-axis and short-axis views).

    • Doppler echocardiography is an excellent tool for assessing the severity of aortic stenosis. Using the modified Bernoulli equation, a maximum instantaneous and mean aortic valve gradient can be derived from the continuous-wave Doppler velocity across the aortic valve.
    • In a laboratory with experienced personnel, Doppler-derived aortic valve gradients are accurate and reproducible and correlate well with those obtained during cardiac catheterization.
    • The transvalvular gradient is dependent on the severity of obstruction and the flow across the valve. In patients with low cardiac output, the valvular stenosis may be severe even though the transvalvular gradient is low. To overcome this problem, 2-dimensional Doppler echocardiography can also provide a reliable estimation of aortic valve area (AVA). The echocardiographic criteria for assessment of aortic stenosis severity are outlined in Table 3.
    • The major limitation of Doppler echocardiography in assessing the severity of aortic stenosis is underestimation of the gradient if the beam is not parallel to the aortic stenosis velocity jet. Thus, in a patient with clinical features of severe aortic stenosis but echo/Doppler findings of mild-to-moderate aortic stenosis, further evaluation with repeat Doppler or catheterization is required. Rarely, Doppler may overestimate the mean gradient in cases of severe anemia (hemoglobin <8 g/dL), a small aortic root, or sequential stenoses in parallel (coexistent LVOT and valvular obstruction). Furthermore, echocardiographic calculation of AVA is highly dependent on accurate measurement of the diameter of the LVOT. In patients with poor transthoracic echocardiographic images, transesophageal echocardiography (TEE) may be used to measure the mean and peak gradient and a planimeter may be used to assess the AVA. Table 2. ACC/AHA Recommendations for Echocardiography in Aortic Stenosis

      Open table in new window

      Table
      IndicationClass
      Diagnosis and assessment of severity of ASI
      Assessment of LV size, function, and/or hemodynamicsI
      Reevaluation of patients with known AS with changing symptoms or signsI
      Assessment of changes in hemodynamic severity and ventricular function in patients with known AS during pregnancyI
      Reevaluation of asymptomatic patients with severe ASI
      Reevaluation of asymptomatic patients with mild-to-moderate AS and evidence of LV dysfunction or hypertrophyIIa
      Routine reevaluation of asymptomatic adult patients with mild AS who have stable physical signs and normal LV size and functionIII
      IndicationClass
      Diagnosis and assessment of severity of ASI
      Assessment of LV size, function, and/or hemodynamicsI
      Reevaluation of patients with known AS with changing symptoms or signsI
      Assessment of changes in hemodynamic severity and ventricular function in patients with known AS during pregnancyI
      Reevaluation of asymptomatic patients with severe ASI
      Reevaluation of asymptomatic patients with mild-to-moderate AS and evidence of LV dysfunction or hypertrophyIIa
      Routine reevaluation of asymptomatic adult patients with mild AS who have stable physical signs and normal LV size and functionIII
      Table 3. Criteria for Determining Severity of Aortic Stenosis

      Open table in new window

      Table
      SeverityMean gradient (mm Hg)Aortic valve area (cm2)
      Mild<25>1.5
      Moderate25-501-1.5
      Severe>50<1
      (or <0.5 cm 2/m 2 body surface area)
      Critical>80<0.5
      SeverityMean gradient (mm Hg)Aortic valve area (cm2)
      Mild<25>1.5
      Moderate25-501-1.5
      Severe>50<1
      (or <0.5 cm 2/m 2 body surface area)
      Critical>80<0.5
  • Radionuclide ventriculography may provide information on LV function, including LV ejection fraction, ESV, and EDV.
  • Multislice computed tomography: Three-dimensional volume quantification of aortic valve calcification demonstrates a close, nonlinear relationship to echocardiographic parameters of severity of aortic stenosis. This method is not yet clinically validated.
  • Cardiac magnetic resonance imaging: Comparison of AVA measurements via echocardiography/Doppler and cardiac magnetic resonance imaging has shown excellent correlation. This method is not yet clinically validated.

Other Tests

  • Electrocardiogram
    • Although the ECG findings may be entirely normal, the principal finding is left ventricular hypertrophy (LVH), which is found in 85% of patients with severe aortic stenosis; however, its absence does not preclude critical aortic stenosis. The correlation between absolute voltages in precordial leads and the severity of obstruction, unlike in children with congenital aortic stenosis, is poor in adults.
    • T-wave inversion and ST-segment depression in leads with predominantly positive QRS complexes are common. ST depression exceeding 0.3 mV in patients with aortic stenosis indicates LV strain and suggests that severe LVH is present. Occasionally, a septal pseudoinfarct pattern can be seen. Left atrial enlargement with a preterminal negative p wave in lead V1 is noted in 80% of severe isolated cases of aortic stenosis.
    • The rhythm usually is normal sinus. Atrial fibrillation and can be seen at late stages or as a consequence of coexistent MV disease or hyperthyroidism.
    • Extension of calcification into the conduction system can cause atrioventricular or intraventricular block in 5% of cases of aortic stenosis. Approximately 10% of all cases of left anterior fascicular block are secondary to calcified aortic valve disease. Ambulatory ECG monitoring frequently shows complex ventricular arrhythmias, particularly in cases with myocardial dysfunction.
  • Chest roentgenogram
    • The cardiac size often is normal, with rounding of the LV border and apex despite significant aortic stenosis. Poststenotic dilatation of the ascending aorta is common.
    • On lateral view, aortic valve calcification is found in almost all adults with hemodynamically significant aortic stenosis. Although its absence on fluoroscopy in individuals older than 35 years rules out severe valvular aortic stenosis, its presence does not prove severe obstruction in individuals older than 60 years.
    • The left atrium may be slightly enhanced, and pulmonary venous hypertension may be seen.
  • Stress testing: Exercise stress testing is usually not needed in patients with severe aortic stenosis to rule out coronary artery disease. However, closely monitored exercise stress testing may be of value to assess exercise capacity in asymptomatic patients. Abnormal results may prove greater disability than the patient would admit. In addition to watching for symptoms on the treadmill, one should also look for hemodynamic abnormalities, such as blood pressure decreases or failure to increase blood pressure normally, which can occur in the absence of symptoms. The test here is not used to screen for coronary disease.
  • Provocative stress testing: This is used in cases when the severity of the aortic stenosis is uncertain because of a small stroke volume and a small mean aortic valve gradient (low-gradient aortic stenosis).
    • Infusion of an inotropic agent such as dobutamine, which results in an increase in stroke volume and heart rate, is usually helpful in establishing the correct diagnosis.
    • Cardiac output and LV and aortic pressures are measured simultaneously and AVA is calculated both before and during dobutamine infusion.
    • In patients with an initially low-pressure gradient but severe aortic stenosis, the measured AVA does not change and the mean-pressure gradient increases significantly with an intravenous dobutamine infusion in. In contrast, in patients who have a low cardiac output due to concomitant myocardial dysfunction rather than due to severe aortic stenosis alone, a minimal increase in aortic valve gradient and the measured AVA usually occurs with dobutamine infusion.

Procedures

Cardiac catheterization

In general, if clinical findings are not consistent with Doppler echocardiogram results, cardiac catheterization is recommended for further hemodynamic assessment. ACC/AHA recommendations for cardiac catheterization in aortic stenosis are summarized in Table 4.

Measurement of simultaneous LV and aortic pressures should be used to assess the transvalvular pressure gradient and cardiac output should be measured for the calculation of AVA.

Exclusion of coronary artery disease by coronary angiography is needed in all patients older than 35 years who are being considered for valve surgery. It also should be performed in patients younger than 35 years if they have LV systolic dysfunction, symptoms/signs suggestive of coronary artery disease, or 2 or more risk factors for premature coronary artery disease, excluding sex. Generally, the incidence of associated coronary artery disease has been reported to be 50% in individuals older than 50 years.

Measuring the left ventricular end-diastolic and systolic volume and calculating the ejection fraction (EF) can quantitate the status of LV systolic pump function. However, EF may underestimate LV performance in the presence of the increased afterload associated with severe aortic stenosis. Since bolus administration of contrast may provoke hemodynamic compromise and assessment of LV function can usually be obtained via echocardiography, contrast ventriculography is rarely indicated.

Table 4. Recommendations for Cardiac Catheterization in Aortic Stenosis

Open table in new window

Table
IndicationClass
Coronary angiography before AVR in patients at risk for CADI
Assessment of severity of AS in symptomatic patients when AVR is planned or when noninvasive tests are inconclusive or a discrepancy exists in the clinical findings regarding severity of AS or the need for surgeryI
Assessment of severity of AS before AVR when noninvasive tests are adequate and concordant with clinical findings and coronary angiography is not neededIIb
Assessment of LV function and severity of AS in asymptomatic patients when noninvasive tests are adequateIII
IndicationClass
Coronary angiography before AVR in patients at risk for CADI
Assessment of severity of AS in symptomatic patients when AVR is planned or when noninvasive tests are inconclusive or a discrepancy exists in the clinical findings regarding severity of AS or the need for surgeryI
Assessment of severity of AS before AVR when noninvasive tests are adequate and concordant with clinical findings and coronary angiography is not neededIIb
Assessment of LV function and severity of AS in asymptomatic patients when noninvasive tests are adequateIII

More on Aortic Stenosis

Overview: Aortic Stenosis
Differential Diagnoses & Workup: Aortic Stenosis
Treatment & Medication: Aortic Stenosis
Follow-up: Aortic Stenosis
Multimedia: Aortic Stenosis
References

References

  1. [Guideline] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. May 21 2003;289(19):2560-72. [Medline].

  2. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. Feb 6 2007;49(5):554-61. [Medline].

  3. Zajarias A, Cribier A. Outcomes and safety of percutaneous aortic valve replacement. Journal of the American College of Cardiology. May 2009;53:1829-36. [Medline].

  4. [Guideline] Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. August 2008;52:676-85. [Medline].

  5. Agarwal A, Kini AS, Attanti S, et al. Results of repeat balloon valvuloplasty for treatment of aortic stenosis in patients aged 59 to 104 years. Am J Cardiol. Jan 1 2005;95(1):43-7. [Medline].

  6. Bauer F, Eltchaninoff H, Tron C, et al. Acute improvement in global and regional left ventricular systolic function after percutaneous heart valve implantation in patients with symptomatic aortic stenosis. Circulation. Sep 14 2004;110(11):1473-6. [Medline].

  7. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. May 2004;109:2302-8. [Medline].

  8. Bonow RO, Carabello B, de Leon AC, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Nov 3 1998;98(18):1949-84. [Medline].

  9. Braunwald E. Heart disease: a textbook of cardiovascular medicine. In: Braunwald E, ed. Aortic Stenosis. 4th ed. Philadelphia, Pa: WB Saunders; 1992:1035-43.

  10. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation. May 20 1997;95(10):2395-400. [Medline].

  11. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. Dec 10 2002;106(24):3006-8. [Medline].

  12. Frank S, Johnson A, Ross J Jr. Natural history of valvular aortic stenosis. Br Heart J. Jan 1973;35(1):41-6. [Medline].

  13. Hanzel GS, Harrity PJ, Schreiber TL, O'Neill WW. Retrograde percutaneous aortic valve implantation for critical aortic stenosis. Catheter Cardiovasc Interv. Mar 2005;64(3):322-6. [Medline].

  14. Hughes BR, Chahoud G, Mehta JL. Aortic stenosis: is it simply a degenerative process or an active atherosclerotic process?. Clin Cardiol. Mar 2005;28(3):111-4. [Medline].

  15. Messika-Zeitoun D, Aubry MC, Detaint D, et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation. Jul 20 2004;110(3):356-62. [Medline].

  16. Novaro GM. Electron beam computed tomography: the latest "stethoscope" for calcific aortic valve disease. Mayo Clin Proc. Oct 2004;79(10):1239-41. [Medline].

  17. O'Rourke RA. Aortic valve stenosis: a common clinical entity. Curr Probl Cardiol. Aug 1998;23(8):434-71. [Medline].

  18. Otto CM. Aortic stenosis and hyperlipidemia: establishing a cause-effect relationship. Am Heart J. May 2004;147(5):761-3. [Medline].

  19. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. May 6 1997;95(9):2262-70. [Medline].

  20. Passik CS, Ackermann DM, Pluth JR, Edwards WD. Temporal changes in the causes of aortic stenosis: a surgical pathologic study of 646 cases. Mayo Clin Proc. Feb 1987;62(2):119-23. [Medline].

  21. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol. Apr 1990;15(5):1012-7. [Medline].

  22. Prasad Y, Bhalodkar NC. Aortic sclerosis--a marker of coronary atherosclerosis. Clin Cardiol. Dec 2004;27(12):671-3. [Medline].

  23. Rahimtoola SH. The year in valvular heart disease. J Am Coll Cardiol. Jan 4 2005;45(1):111-22. [Medline].

  24. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. Sep 7 2004;110(10):1180-2. [Medline].

  25. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. Sep 7 2004;110(10):1291-5. [Medline].

  26. Selzer A. Changing aspects of the natural history of valvular aortic stenosis. N Engl J Med. Jul 9 1987;317(2):91-8. [Medline].

  27. Vahanian A, Palacios IF. Percutaneous approaches to valvular disease. Circulation. Apr 6 2004;109(13):1572-9. [Medline].

Further Reading

Keywords

aortic stenosis, AS, valvular aortic stenosis, valvular AS, aorta stenosis, aortic valve surgery, heart failure, syncope, angina pectoris, pulsus parvus et tardus, heart valve obstruction, aortic obstruction, aortic valve obstruction, aortic valve replacement, AVR, sudden cardiac death, SCD, calcific embolization, infective endocarditis

Contributor Information and Disclosures

Author

John A McPherson, MD, FACC, FSCAI, Assistant Professor of Medicine, Division of Cardiovascular Medicine, Medical Director of Cardiovascular Intensive Care Unit, Vanderbilt Heart and Vascular Institute
John A McPherson, MD, FACC, FSCAI is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, Society for Cardiac Angiography and Interventions, Society of Critical Care Medicine, and Tennessee Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Alan D Forker, MD, Professor of Medicine, Program Director of Cardiovascular Fellowship, University of Missouri at Kansas City School of Medicine; Director, Outpatient Lipid Diabetes Research Center, MidAmerica Heart Institute of St Luke's Hospital
Alan D Forker, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, American Society of Hypertension, and Phi Beta Kappa
Disclosure: Research Grant Grant/research funds Hospital contracts to do research; I am a hospital employee with no personal profit; Speakers Bureau Honoraria Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Steven J Compton, MD, FACC, FACP, Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals
Steven J Compton, MD, FACC, FACP is a member of the following medical societies: Alaska State Medical Association, American College of Cardiology, and American College of Physicians
Disclosure: Nothing to disclose.

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD, Professor and Executive Vice Chairman, Department of Medicine, University of Texas Health Science Center at San Antonio
Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.